Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099162 | 1.00 | CCKBR (0.57) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL12099159 | 1.00 | CCKBR (0.57) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL12099260 | 0.89 | CCKBR (0.53) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL1515162 | 0.88 | CCKBR (0.50) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL12099087 | 0.88 | CCKBR (0.50) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL11964637 | 0.88 | CCKBR (0.61) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2265093 | 0.88 | CCKBR (0.61) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL12099099 | 0.87 | CCKBR (0.53) | CCKBRLMNAPGR | |
| SCHEMBL1514989 | 0.87 | CCKBR (0.53) | CCKBRLMNAPGR | |
| SCHEMBL1515087 | 0.87 | CCKBR (0.52) | CCKBRLMNAMEN1ALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673897-B2 | Benzodiazepinone compounds and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2011035124-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232067-A1 | BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME | TPH1, GABBR1, RORC | CCKBR 748/4885LMNA 4326/4885MEN1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.